S. Parasuraman

发表

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.

J. Sosman, G. Schwartz, M. Postow, 2014 .

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

K. Cole, G. Caponigro, P. Raman, 2016, Clinical Cancer Research.

Prevention of pulmonary embolism in general surgery patients.

S. Goldhaber, S. Parasuraman, U. Zurawska, 2007, Circulation.

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

G. Shapiro, J. Dobson, J. Infante, 2016, Clinical Cancer Research.

Cancer Therapy : Preclinical Dual CDK 4 / CDK 6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013 .

Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy

S. Goldhaber, S. Parasuraman, A. Seddighzadeh, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism.

S. Goldhaber, M. Gerhard-Herman, S. Parasuraman, 2007, Thrombosis and haemostasis.

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma

B. Weir, B. Crompton, K. Stegmaier, 2015, Oncotarget.

A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.

G. Shapiro, J. Infante, V. Ribrag, 2014 .

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

W. Sellers, G. Caponigro, Alice T. Loo, 2013 .

Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.

G. Shapiro, J. Infante, V. Ribrag, 2013 .

Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Suzanne F. Jones, J. Bendell, R. Cohen, 2010 .

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Andrew C. Wood, Daniel Martinez, Sharon J. Diskin, 2013, Clinical Cancer Research.

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

M. Fischer, B. Geoerger, J. Dobson, 2017, Clinical Cancer Research.

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy

T. Choueiri, M. Atkins, R. Arbeit, 2021, Investigational New Drugs.

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

R. Neuwirth, K. Venkatakrishnan, C. Takimoto, 2010 .

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

M. Ross, L. Aicher, R. Pierce, 2022, Cancer research communications.

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2009 .

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venous thromboembolism in children.

S. Goldhaber, S. Parasuraman, 2006, Circulation.

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

P. Moreau, X. Leleu, T. Robak, 2010 .

Pharmacokinetics of LEE011, a CDK4/6 Inhibitor, in Adult and Pediatric Patients With Advanced Tumors

C. Davis, A. Chakraborty, A. Matano, 2014 .

455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D-CDK4/6 PATHWAY-ACTIVATED TUMORS.

B. Geoerger, M. DeWire, F. Bourdeaut, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA.

J. Sosman, W. Miller, M. Postow, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

R. Neuwirth, F. Cabanillas, O. O’Connor, 2010 .

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.

K. Kelly, L. Nadauld, J. Grilley-Olson, 2016 .

Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: the St. Jude Children's Research Hospital experience.

T. Merchant, A. Pappo, C. Poquette, 1999, Journal of pediatric hematology/oncology.

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

T. Yap, G. Falchook, S. Parasuraman, 2021 .

866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

T. Yap, R. Abo, G. Falchook, 2021, Journal for ImmunoTherapy of Cancer.

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

K. Cole, G. Caponigro, J. Maris, 2013, Clinical Cancer Research.

Successful implementation of a novel trial model: The Signature program.

L. Nadauld, A. Alva, S. Piha-Paul, 2015 .

Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

B. Cheson, S. Parasuraman, P. Rosen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.